BACKGROUND:The Hartmann's operation, although less frequently performed today, is still used when initial colonic anastomosis is too risky in the short term. However, the subsequent procedure to restore gastrointestinal continuity is associated with significant morbidity and mortality.PATIENTS AND METHODS:The review of an institutional review board (IRB)-approved prospectively maintained database provided data on the Hartmann's reversal procedure performed by either laparoscopic or open technique at our institution. The data collected included: demographic data, operative approach, conversion for laparoscopic cases and perioperative morbidity and mortality.RESULTS:Over a 14-year period from January 1997 to August 2011, 74 Hartmann's reversal procedures were performed (laparoscopic surgery—49, open surgery—25). The average age was 55 years for the laparoscopic and 57 years for the open surgery group, respectively. Male patients represent 61% of both groups. There was no significant difference in operative time between the two groups (149 min vs 151 min; P = 0.95), and there was a tendency to lower morbidity (3/49—7.3% vs 4/25—16%; P = 0.24) in the laparoscopic surgery group. In the laparoscopic group, eight patients (16.3%) were converted to open surgery, mostly due to severe adhesions. The length of hospital stay was significantly shorter for the laparoscopic group (5 days vs 7 days; P = 0.44).CONCLUSIONS:The Hartmann's reversal procedure can be safely performed in the majority of the cases using a laparoscopic approach with a low morbidity rate and achieving a shorter hospital stay.

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, and although new therapeutic approaches have been recently evaluated, overall patient survival is still poor. Thus, new effective and selective clinical treatments are urgently needed. An analysis of data from large-scale, high-throughput drug screening cell line projects identified Bosutinib, a Src/Abl inhibitor that is currently used for the treatment of chronic myelogenous leukemia, as a candidate drug to treat HNSCC. Using a panel of HNSCC-derived cell lines, we found that treatment with Bosutinib reduced cell proliferation and induced apoptosis of sensitive cell lines. The drug rapidly inhibited Src and EGFR (epidermal growth factor receptor) phosphorylation, and sensitivity to Bosutinib was correlated with the activation status of EGFR. Similar findings were observed in in vivo xenograft assays using HNSCC derived cells. Moreover, in the presence of mutations in PIK3CA, the combination of Bosutinib with the PI3Kα inhibitor Alpelisib showed a synergistic effect. These results suggest that Bosutinib could be a new effective drug for the treatment of HNSCC, particularly in tumors with high EGFR activity. Its combination with Alpelisib could especially benefit patients bearing activating mutations of PIK3CA.

(*) Tanto el desarrollo como la elaboración del modelo ha sido financiado por una beca no finalista otorgada por Medtronic Ibérica S.A. a CORE Research, quien ha llevado a cabo los análisis en todo momento y con total autonomía. RESUMENFundamento: El uso de bombas de infusión continua de insulina (BICI) para la diabetes mellitus tipo 1 (DM1) se ha relacionado con un mejor control metabólico al compararlo con las múltiples dosis de insulina (MDI). Este mejor control puede traducirse en una disminución de las complicaciones asociadas a la DM1 y por lo tanto una reducción de los costes asociados. Sin embargo el uso de esta terapia ha quedado mermado, al menos en parte, debido a su mayor coste inicial de adquisición. El objetivo del presente estudio fue estimar las consecuencias clínicas y económicas del uso de BICI frente a MDI a través de un análisis de coste-utilidad.Métodos: Se adaptó un modelo matemático de simulación que emplea datos clínicos y económicos de ámbito nacional, para simular las consecuencias clínicas y económicas a largo plazo de un paciente con DM1. El horizonte temporal fue el de toda la vida del paciente, incluyendo sólo costes directos sanitarios, y actualizando tanto costes como beneficios a una tasa del 3% anual.Resultados: En el caso base los pacientes tratados con BICI experimentaron una ganancia de vida de 0,890 años (p<0,05) y 0,852 AVACs (p<0,05). El tratamiento con BICI produce un coste medio incremental de 25.523 ? (p<0,05) por paciente tratado, lo que nos condujo a un ratio coste-utilidad incremental de 29.947 ?/AVAC [IC 95% (29.519, 30.375)].Conclusiones: La mejora en el control glucémico en pacientes con BICI se asoció a una reducción del coste global del manejo de pacientes con DM1, y resultó tener una relación coste-utilidad favorable al compararla con el tratamiento convencional MDI.Palabras clave: Diabetes mellitus Tipo 1. Coste-utilidad. Bombas de insulina. Modelo Económico. ABSTRACT Cost-Utility Analysis of Iinsulin Pumps Compared to Multiple Daily doses of Insulin in Patients with Type 1 Diabetes Mellitus in SpainBackground: The use of continuous subcutaneous insulin infusion (CSII) for treating Type I diabetes mellitus (DM1) has been related to better metabolic control compared it to daily multiple insulin injections (DMI) and thus to a lowering of the related costs. However, this therapy is now being used to a lesser extent due, at least partially, to the higher initial cost of purchase. This study is aimed at estimating the clinical and economic consequences of using CSII as compared to DMI by means of a cost-utility analysis.

No abstract